Sunday 11 October 2026 Export all AMGN data to Excel Powerpack

Amgen Inc.

AMGN Healthcare Drug Manufacturers General

Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.

414.87 7.43 +1.82%
Market cap
$220.3B
P/E
25.6×
Fwd P/E
22.7×
Dividend yield
2.40%
F-score
7/9
Altman Z
1.69
Beneish M
−2.27
Dividend safety
56/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
22.33 24.30 22.84 21.66

+8 more quarters

P/S ratio
5.13 5.10 4.79 4.22
P/FCF ratio
20.07 23.28 22.97 13.67
P/Operating CF
48.86 86.80 109.85 32.41
P/B ratio
16.73 20.67 20.34 15.78
EV/Sales
6.27 6.32 6.03 5.48
EV/EBITDA
14.48 14.83 14.34 12.85
EV/FCF
24.52 28.82 28.90 17.74
Current Ratio
1.37 1.26 1.14 1.28
Net Debt/EBITDA
9.36 11.97 11.81 10.66
Debt/Equity
4.90 6.24 6.31 5.67
Earnings Yield
4.48% 4.12% 4.38% 4.62%
Free Cash Flow Yield
4.98% 4.30% 4.35% 7.31%
Free Cash Flow per Share
6.46 2.74 1.79 7.90
Book value per Share
21.64 17.02 16.09 17.88
Free Cash Flow
3,489.00 1,477.00 961.00 4,248.00
EV/EBIT
20.90 22.26 24.40 22.72
Other line items

Show all line items

Columns are period end dates